Repositorio Institucional de la Universidad de Oviedo

O-5. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study

Author:

Vogel, A.; Chan, S.; Furuse, J.; Tak, W.; Masi, G.; Varela Calvo, María; Kim, J.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; Makowsky, M.; Marcovitz, M.; Negro, A.; Abou Alfa, G.

Publication date:

2022

Publisher version:

http://dx.doi.org/10.1016/j.annonc.2022.04.446

Descripción física:

p. S380-S381

Description:

Resumen presentado al World Congress on Gastrointestinal Cancer (24th. 2022. Barcelona)

URI:

http://hdl.handle.net/10651/66955

ISSN:

0923-7534; 1569-8041

DOI:

10.1016/j.annonc.2022.04.446

Patrocinado por:

AstraZeneca